Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMN310 in healthy volunteers
NCT06105528Phase 1Completed
- Sponsor
- ProMIS Neurosciences
- Start
- Nov 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PMN310 in Alzheimer's disease (AD) (5 cohorts), sponsored by ProMIS Neurosciences. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 85 days, Incidence of Clinically Significant Abnormal Findings in Laboratory Assessments at 85 days and 3 more. Started Nov 2023; status: completed.
02
Drugs
PMN310
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06105528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06105528.